News | November 01, 2021
Dr Reddys Laboratories posts Q2FY22 PAT at Rs 992 Cr
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
Acute therapies continue to report strong growth compared to chronic ones.
Collaboration designed to bring reproductive health screening capabilities to hospitals and clinics across the country
This strategic collaboration will enable continued innovation in cancer care
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The company plans to raise US $ 15 million
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
Subscribe To Our Newsletter & Stay Updated
